ArticleBMC global and public health2026
A national geostatistical survey for schistosomiasis and soil-transmitted helminths in Zimbabwe following interruption of preventive chemotherapy.
Article in BMC global and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchistosomiasis and soil-transmitted helminthiases (STH) are targeted for elimination as public health problems (EPHP) in Zimbabwe by 2030. A 2018 impact survey demonstrated prevalence below EPHP thresholds following seven rounds of annual preventive chemotherapy (PC). However, the COVID-19 pandemic caused a three-year suspension of PC. We conducted a nationwide geostatistical impact assessment to estimate prevalence at ward-level and evaluated impact of PC interruption relative to 2018 results using a quasi-experimental design.
methodsThe cross-sectional survey in 2021 targeted 11,600 school-aged children (SAC) and sub-sets of pre-SAC and adults. Sampling was optimised to achieve 90% correct classification of wards (N = 1,961) using geostatistical predictions from 2018 impact data. 200 schools were selected with inclusion proportional to predicted Schistosoma haematobium prevalence. All SAC provided urine and stool samples analysed by urine filtration and Kato-Katz. Geostatistical models incorporating environmental covariates were fitted and used to generate high-resolution prevalence predictions.
resultsData from 11,190 participants indicated a national schistosomiasis prevalence of 7.0% (95% CI 5.0-9.8%) including focal recrudescence of S. mansoni. Heavy-intensity infection recrudesced above 1% EPHP threshold (1.4%, 95% CI 0.9-2.0). STH prevalence increased though remained low (1.4%, 95% CI 1.0-2.1%), with few moderate-heavy infections (< 0.1%, 95% CI < 0.1-1.2). Geostatistical predictions delineated key spatial heterogeneity: 98.9% of wards exceeded 2% schistosomiasis prevalence (17,909,432 people), 37.2% required annual PC (≥ 10% prevalence; 6,473,455 people), and 33.4% wards exceeded 2% prevalence for STH (biennial PC).
conclusionsPC suspension led to recrudescence of schistosomiasis and smaller increases in STH prevalence. These findings emphasise the risk of pausing PC even in low or moderate prevalence settings. Continued surveillance and tailored PC are essential to achieve 2030 goals, with geostatistical outputs supporting precision interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.